Mitoxantrone exerts both cytotoxic and immunoregulatory effects on activated microglial cells

Immunopharmacology and Immunotoxicology

Volumn 34, Issue 1, 2012, Pages 36-41

  Li, Jun Min ^a   Yang, Yan ^a   Zhu, Ping ^a   Zheng, Fang ^a   Gong, Fei Li ^a   Mei, Yuan Wu ^a  

^a HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

Author keywords

Cytotoxicity; Immunoregulation; Microglia; Mitoxantrone; Multiple sclerosis

Indexed keywords

INTERLEUKIN 10; INTERLEUKIN 23P19; MITOXANTRONE;

ANIMAL CELL; APOPTOSIS; ARTICLE; CELL DEATH; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG CYTOTOXICITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; IMMUNOMODULATION; IMMUNOREGULATION; MICROGLIA; MOUSE; MULTIPLE SCLEROSIS; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; ANTINEOPLASTIC AGENTS; BLOOD-BRAIN BARRIER; CELL DEATH; CELL LINE; CELL SURVIVAL; CYTOTOXINS; GENE EXPRESSION REGULATION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INTERLEUKIN-10; INTERLEUKIN-23 SUBUNIT P19; MICE; MICROGLIA; MITOXANTRONE; MULTIPLE SCLEROSIS; NERVE TISSUE PROTEINS; T-LYMPHOCYTES;

EID: 84055193234     PISSN: 08923973     EISSN: 15322513     Source Type: Journal    
DOI: 10.3109/08923973.2011.572890     Document Type: Article

References (39)

1. Steinman, L. Multiple sclerosis: a two-stage disease. Nat Immunol 2001, 2, 762-764.
2. Neuhaus, O., Kieseier, B.C., Hartung, H.P. Mechanisms of mitoxantrone in multiple sclerosis-what is known? J Neurol Sci 2004, 223, 25-27. (Pubitemid 38903257)
3. Cua, D.J., Sherlock, J., Chen, Y., Murphy, C.A., Joyce, B., Seymour, B., Lucian, L., To, W., Kwan, S., Churakova, T., Zurawski, S., Wiekowski, M., Lira, S.A., Gorman, D., Kastelein, R.A., Sedgwick, J.D. Interleukin-23 rather than interleukin-12 is the critical cytokine for autoimmune inflammation of the brain. Nature 2003, 421, 744-748. (Pubitemid 36227625)
4. Langrish, C.L., Chen, Y., Blumenschein, W.M., Mattson, J., Basham, B., Sedgwick, J.D., McClanahan, T., Kastelein, R.A., Cua, D.J. IL-23 drives a pathogenic T cell population that induces autoimmune inflammation. J Exp Med 2005, 201, 233-240. (Pubitemid 40189432)
5. Fitzgerald, D.C., Zhang, G.X., El-Behi, M., Fonseca-Kelly, Z., Li, H., Yu, S., Saris, C.J., Gran, B., Ciric, B., Rostami, A. Suppression of autoimmune inflammation of the central nervous system by interleukin 10 secreted by interleukin 27-stimulated T cells. Nat Immunol 2007, 8, 1372-1379. (Pubitemid 350131174)
6. Chen, Y., Inobe, J., Kuchroo, V.K., Baron, J.L., Janeway, C.A. Jr. Weiner, H.L. Oral tolerance in myelin basic protein T-cell receptor transgenic mice: suppression of autoimmune encephalomyelitis and dose-dependent induction of regulatory cells. Proc Natl Acad Sci USA 1996, 93, 388-391. (Pubitemid 26038164)
7. Bettelli, E., Das, M.P., Howard, E.D., Weiner, H.L., Sobel, R.A., Kuchroo, V.K. IL-10 is critical in the regulation of autoimmune encephalomyelitis as demonstrated by studies of IL-10- and IL-4- deficient and transgenic mice. J Immunol 1998, 161, 3299-3306.
8. Zhao, Z., Yu, S., Fitzgerald, D.C., Elbehi, M., Ciric, B., Rostami, A.M., Zhang, G.X. IL-12R beta 2 promotes the development of CD4+CD25+ regulatory T cells. J Immunol 2008, 181, 3870-3876.
9. Smith, I.E. Mitoxantrone (novantrone): a review of experimental and early clinical studies. Cancer Treat Rev 1983, 10, 103-115. (Pubitemid 13001898)
10. Vollmer, T., Stewart, T., Baxter, N. Mitoxantrone and cytotoxic drugs' mechanisms of action. Neurology 2010, 74 (Suppl 1), S41-S46.
11. Jain, K.K. Evaluation of mitoxantrone for the treatment of multiple sclerosis. Expert Opin Investig Drugs 2000, 9, 1139-1149. (Pubitemid 30255573)
12. Neuhaus, O., Kieseier, B.C., Hartung, H.P. Therapeutic role of mitoxantrone in multiple sclerosis. Pharmacol Ther 2006, 109, 198-209. (Pubitemid 41740821)
13. Neuhaus, O., Wiendl, H., Kieseier, B.C., Archelos, J.J., Hemmer, B., Stüve, O., Hartung, H.P. Multiple sclerosis: mitoxantrone promotes differential effects on immunocompetent cells in vitro. J Neuroimmunol 2005, 168, 128-137. (Pubitemid 41396410)
14. Gbadamosi, J., Buhmann, C., Tessmer, W., Moench, A., Haag, F., Heesen, C. Effects of mitoxantrone on multiple sclerosis patients' lymphocyte subpopulations and production of immunoglobulin, TNF-alpha and IL-10. Eur Neurol 2003, 49, 137-141. (Pubitemid 36359460)
15. Chan, A., Weilbach, F.X., Toyka, K.V., Gold, R. Mitoxantrone induces cell death in peripheral blood leucocytes of multiple sclerosis patients. Clin Exp Immunol 2005, 139, 152-158. (Pubitemid 40066141)
16. Kopadze, T., Dehmel, T., Hartung, H.P., Stüve, O., Kieseier, B.C. Inhibition by mitoxantrone of in vitro migration of immunocompetent cells: a possible mechanism for therapeutic efficacy in the treatment of multiple sclerosis. Arch Neurol 2006, 63, 1572-1578. (Pubitemid 44748799)
17. Fidler, J.M., DeJoy, S.Q., Gibbons, J.J., Jr. Selective immunomodulation by the antineoplastic agent mitoxantrone. I. Suppression of B lymphocyte function. J Immunol 1986, 137, 727-732. (Pubitemid 16045109)
18. Pelfrey, C.M., Cotleur, A.C., Zamor, N., Lee, J.C., Fox, R.J. Immunological studies of mitoxantrone in primary progressive MS. J Neuroimmunol 2006, 175, 192-199. (Pubitemid 43765738)
19. Carson, M.J. Microglia as liaisons between the immune and central nervous systems: functional implications for multiple sclerosis. Glia 2002, 40, 218-231. (Pubitemid 35337379)
20. Brahmachari, S., Jana, A., Pahan, K. Sodium benzoate, a metabolite of cinnamon and a food additive, reduces microglial and astroglial inflammatory responses. J Immunol 2009, 183, 5917-5927.
21. Kuhlmann, T., Wendling, U., Nolte, C., Zipp, F., Maruschak, B., Stadelmann, C., Siebert, H., Brück, W. Differential regulation of myelin phagocytosis by macrophages/microglia, involvement of target myelin, Fc receptors and activation by intravenous immunoglobulins. J Neurosci Res 2002, 67, 185-190. (Pubitemid 34052037)
22. Nagai, A., Nakagawa, E., Hatori, K., Choi, H.B., McLarnon, J.G., Lee, M.A., Kim, S.U. Generation and characterization of immortalized human microglial cell lines: expression of cytokines and chemokines. Neurobiol Dis 2001, 8, 1057-1068. (Pubitemid 34017099)
23. Veroni, C., Gabriele, L., Canini, I., Castiello, L., Coccia, E., Remoli, M.E., Columba-Cabezas, S., Arica, E., Aloisi, F., Agresti, C. Activation of TNF receptor 2 in microglia promotes induction of anti-inflammatory pathways. Mol Cell Neurosci 2010, 45, 234-244.
24. Lu, K., Savaraj, N., Loo, T.L. Pharmacological disposition of 1,4- dihydroxy-5-8-bis[[2 [(2-hydroxyethyl)amino]ethyl]amino]-9,10- anthracenedione dihydrochloride in the dog. Cancer Chemother Pharmacol 1984, 13, 63-66.
25. Baker, D., O'Neill, J.K., Davison, A.N., Turk, J.L. Control of immunemediated disease of the central nervous system requires the use of a neuroactive agent: elucidation by the action of mitoxantrone. Clin Exp Immunol 1992, 90, 124-128.
26. Piao, W.H., Wong, R., Bai, X.F., Huang, J., Campagnolo, D.I., Dorr, R.T., Vollmer, T.L., Shi, F.D. Therapeutic effect of anthracenebased anticancer agent ethonafide in an animal model of multiple sclerosis. J Immunol 2007, 179, 7415-7423.
27. Hou, R.C., Chen, H.L., Tzen, J.T., Jeng, K.C. Effect of sesame antioxidants on LPS-induced NO production by BV2 microglial cells. Neuroreport 2003, 14, 1815-1819. (Pubitemid 37372609)
28. Kim, W.K., Jang, P.G., Woo, M.S., Han, I.O., Piao, H.Z., Lee, K., Lee, H., Joh, T.H., Kim, H.S. A new anti-inflammatory agent KL-1037 represses proinflammatory cytokine and inducible nitric oxide synthase (iNOS) gene expression in activated microglia. Neuropharmacology 2004, 47, 243-252. (Pubitemid 38824648)
29. Vermes, I., Haanen, C., Steffens-Nakken, H., Reutelingsperger, C. A novel assay for apoptosis. Flow cytometric detection of phosphatidylserine expression on early apoptotic cells using fluorescein labelled Annexin V. J Immunol Methods 1995, 184, 39-51.
30. Rieckmann, P., Toyka, K.V., Bassetti, C., Beer, K., Beer, S., Buettner, U., Chofflon, M., Götschi-Fuchs, M., Hess, K., Kappos, L., Kesselring, J., Goebels, N., Ludin, H.P., Mattle, H., Schluep, M., Vaney, C., Baumhackl, U., Berger, T., Deisenhammer, F., Fazekas, F., Freimüller, M., Kollegger, H., Kristoferitsch, W., Lassmann H., Markut, H., Strasser-Fuchs, S., Vass, K., Altenkirch, H., Bamborschke, S., Baum, K., Benecke, R., Brück, W., Dommasch, D., Elias, W.G., Gass, A., Gehlen, W., Haas, J., Haferkamp, G., Hanefeld, F., Hartung, H.P., Heesen, C., Heidenreich, F., Heitmann, R., Hemmer, B., Hense, T., Hohlfeld, R., Janzen, R.W., Japp, G., Jung, S., Jügelt, E., Koehler, J., Kölmel, W., König, N., Lowitzsch, K., Manegold, U., Melms, A., Mertin, J., Oschmann, P., Petereit, H.F., Pette, M., Pöhlau, D., Pohl, D., Poser, S., Sailer, M., Schmidt, S., Schock, G., Schulz, M., Schwarz, S., Seidel, D., Sommer, N., Stangel, M., Stark, E., Steinbrecher, A., Tumani, H., Voltz, R., Weber, F., Weinrich, W. Weissert, R., Wiendl, H., Wiethölter, H., Wildemann, U., Zettl, U.K., Zipp, F., Zschenderlein, R., Izquierdo, G., Kirjazovas, A., Packauskas, L., Miller, D., Koncan Vracko, B., Millers, A., Orologas, A., Panellus, M., Sindic, C.J., Bratic, M., Svraka, A., Vella, N.R., Stelmasiak, Z., Selmaj, K., Bartosik-Psujik, H., Mitosek-Szewczyk, K., Belniak, E., Mochecka, A., Bayas, A., Chan, A., Flachenecker, P., Gold, R., Kallmann, B., Leussink, V., Mäurer, M., Ruprecht, K., Stoll, G., Weilbach, F.X.; Multiple Sclerosis Therapy Consensus Group. Escalating immunotherapy of multiple sclerosis-new aspects and practical application. J Neurol 2004, 251, 1329-1339.
31. Hartung, H.P., Gonsette, R., König, N., Kwiecinski, H., Guseo, A., Morrissey, S.P., Krapf, H., Zwingers, T.; Mitoxantrone in Multiple Sclerosis Study Group (MIMS). Mitoxantrone in progressive multiple sclerosis: a placebo-controlled, double-blind, randomised, multicentre trial. Lancet 2002, 360, 2018-2025. (Pubitemid 36026580)
32. Kim, H.J., Ifergan, I., Antel, J.P., Seguin, R., Duddy, M., Lapierre, Y., Jalili, F., Bar-Or, A. Type 2 monocyte and microglia differentiation mediated by glatiramer acetate therapy in patients with multiple sclerosis. J Immunol 2004, 172, 7144-7153. (Pubitemid 38669158)
33. Zhu, J., Paul, W.E. Heterogeneity and plasticity of T helper cells. Cell Res 2010, 20, 4-12.
34. Krakauer, M., Sorensen, P., Khademi, M., Olsson, T., Sellebjerg, F. Increased IL-10 mRNA and IL-23 mRNA expression in multiple sclerosis: interferon-beta treatment increases IL-10 mRNA expression while reducing IL-23 mRNA expression. Mult Scler 2008, 14, 622-630. (Pubitemid 351954404)
35. Li, Y., Chu, N., Hu, A., Gran, B., Rostami, A., Zhang, G.X. Increased IL-23p19 expression in multiple sclerosis lesions and its induction in microglia. Brain 2007, 130, 490-501. (Pubitemid 46181102)
36. Li, J., Gran, B., Zhang, G.X., Ventura, E.S., Siglienti, I., Rostami, A., Kamoun, M. Differential expression and regulation of IL-23 and IL-12 subunits and receptors in adult mouse microglia. J Neurol Sci 2003, 215, 95-103. (Pubitemid 37272203)
37. Mekala, D.J., Alli, R.S., Geiger, T.L. IL-10-dependent infectious tolerance after the treatment of experimental allergic encephalomyelitis with redirected CD4+CD25+ T lymphocytes. Proc Natl Acad Sci USA 2005, 102, 11817-11822. (Pubitemid 41170808)
38. O'Neill, E.J., Day, M.J., Wraith, D.C. IL-10 is essential for disease protection following intranasal peptide administration in the C57BL/6 model of EAE. J Neuroimmunol 2006, 178, 1-8. (Pubitemid 44307342)
39. Stewart, D.J., Green, R.M., Mikhael, N.Z., Montpetit, V., Thibault, M., Maroun, J.A. Human autopsy tissue concentrations of mitoxantrone. Cancer Treat Rep 1986, 70, 1255-1261 (Pubitemid 17184289)